OncoZenge AB (8LY) Price & Analysis
8LY Stock Chart & Stats
- Day’s Range
- EUR 0.26 - EUR 0.26
- 52-Week Range
- EUR 0.26 - EUR 0.63
- Previous Close
- EUR 0.27
- Volume
- 0
- Average Volume (3M)
- 0
- Market Cap
- EUR 7.80M
- Enterprise Value
- EUR 108.32M
- Total Cash (Recent Filing)
- EUR 749.00K
- Total Debt (Recent Filing)
- EUR 7.50M
- Price to Earnings (P/E)
- ―
- Beta
- 0.61
- Next Earnings
- Nov 11, 2026
- EPS Estimate
- N/A
- Next Dividend Ex-Date
- N/A
- Dividend Yield
- N/A
Bulls Say, Bears Say
Bulls Say
Revenue Growth
Revenue more than doubled from the 2025 level, indicating improving commercialization traction for the company’s products. Although the base remains small, sustained growth could gradually improve operating leverage and provide a stronger foundation for future development and market expansion.
Focused Oncology Portfolio
A focused position in oncology supportive care gives OncoZenge a clearly defined therapeutic purpose and development strategy. Concentrating on severe cancer-related pain and oral mucositis may help align product development and commercialization resources around a specific unmet-care area.
Improving Free Cash Flow
Free cash flow remains negative, but its improvement versus 2025 is a constructive direction in the company’s funding profile. If this trend continues alongside revenue growth, it could moderate the pace of external financing needs and improve financial resilience over time.
Bears Say
Persistent Net Losses
The company’s cost base remains far larger than its current revenue, producing substantial operating and net losses. Continued losses limit internally generated funding, weaken earnings quality, and make future progress dependent on significant commercialization gains or additional external capital.
Heavy Cash Burn
OncoZenge is still consuming cash at a high rate relative to its revenue scale, consistent with an R&D-heavy business funding operations externally. Persistent negative operating cash flow reduces financial flexibility and increases the importance of improving revenue and controlling expenses.
Negative Equity And Leverage
Negative equity is a major solvency warning and leaves the company with limited balance-sheet flexibility. Debt of approximately 7.5m alongside negative equity increases reliance on external funding and may constrain the ability to absorb setbacks or finance growth on favorable terms.
OncoZenge AB News
8LY FAQ
What was OncoZenge AB’s price range in the past 12 months?
What is OncoZenge AB’s market cap?
When is OncoZenge AB’s upcoming earnings report date?
How were OncoZenge AB’s earnings last quarter?
Is OncoZenge AB overvalued?
Does OncoZenge AB pay dividends?
What is OncoZenge AB’s EPS estimate?
How many shares outstanding does OncoZenge AB have?
What happened to OncoZenge AB’s price movement after its last earnings report?
Which hedge fund is a major shareholder of OncoZenge AB?
What is the TipRanks Smart Score and how is it calculated?
Company Description
OncoZenge AB
OncoZenge AB (publ) operates as a pharmaceutical company with a focus on developing medical solutions that offer supportive care for cancer patients. A significant product in its pipeline is BupiZenge, which has successfully completed Phase 2 clinical trials for the management of oral mucositis. This company was established in 2020 and conducts its operations from its headquarters in Bromma, Sweden. Notably, OncoZenge AB (publ) is a subsidiary entity of Moberg Pharma AB (publ).
- Sector
- Healthcare
- Industry
- Biotechnology
- CEO
- Stian Kildal
- Employees
- 1
- Website
- www.oncozenge.se
- Address
- Gustavslundsvagen 34, Bromma, AB, 167 51, SE
OncoZenge AB (8LY) Earnings & Revenues
Technical Analysis
Overall Consensus
| Indicator | Bullish | Neutral | Bearish |
|---|---|---|---|
| Overall Consensus | 6 | 2 | 14 |
| Technical Analysis | 6 | 2 | 2 |
| Moving Averages | 0 | 0 | 12 |